Announced
Synopsis
DIC, a chemical company, agreed to acquire the Canadian business of PCAS, a biotechnology company, for €88m ($97m). "PCAS’ potential decision to divest its Canadian subsidiary and the execution of the related agreements remain in any case subject to the full completion of the mandatory information-consultation process of the competent workers’ councils, after authorization of PCAS’ Supervisory Board and Seqens, its majority shareholder," PCAS.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.